MultiOmyx: High-Order Multiplexing Methodology

NeoGenomics introduces MultiOmyx, a proprietary, multiplexing methodology that enables analysis of dozens of proteins and DNA biomarkers in a single tissue section. Instead of being able to study one or two disease markers at a time, MultiOmyx studies up to 60 biomarkers in a single tumor slice. It also uncovers the relationship between markers which could yield new insights and a more complete picture of tumor behavior.


The Key Benefits of MultiOmyx Include:

Learn More

Download a digital version of our MultiOmyx Poster:

Latest MultiOmyx News

Presented:

Type: Poster, MultiOmyx

PD-1 and LAG-3 synergize to drive tumor-infiltration of T cytotoxic cells in NSCLC tumors

Presented at European Society For Medical Oncology (ESMO) Immuno-Oncology Congress

Download Now

Presented:

Type: Poster, MultiOmyx

An Integrated Multiplexing Approach Identifies IDO1 as a Biomarker for Recurrence of Rare Ovarian Granulosa Cell Tumors

Presented at The Society for Immunotherapy of Cancer (SITC)

Download Now

Presented:

Type: Poster, MultiOmyx

An Integrated Multiplexing Approach for the Immunoprofiling of the Tumor Microenvironment of Ovarian Granulosa Cell Tumors

Presented at European Organisation for Research and Treatment of Cancer

Download Now